SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

MIGI is trending due to its potential for a short squeeze, fueled by a low float and high short interest, as well as its upcoming presentation at an emerging growth conference. Community members are actively discussing the company's shift towards AI and digital infrastructure, viewing it as undervalued compared to its peers, and anticipating potential catalysts from the conference. The stock's volatile price action and history of explosive moves are also contributing to the heightened interest.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending due to a mixed earnings report, with concerns arising from increased spending on AI infrastructure and rising debt despite strong cloud growth and a large backlog. Community discussions revolve around whether Oracle can effectively monetize its AI investments, with some questioning the long-term viability of its strategy, while others see a buying opportunity amid the selloff. The broader market is reacting, with some fearing a potential AI bubble burst.

AXIL Brands, Inc. engages in the manufacture, market, sale and distribution of hearing and audio enhancement, and protection products. It operates through the Hearing Enhancement and Protection, and Hair Care and Skin Care segments. The Hearing Enhancement and Protection segment includes ear buds, earmuffs, ear plugs, outdoor speakers, and ear care items. The Hair Care and Skin Care segment focuses on expanding its business-to-business salon sales through its network of domestic and international distributors. The company was founded on May 21, 2015 and is headquartered in Beverly Hills, CA.

AXIL Brands Inc.

AXIL Brands is trending following news of a national retail distribution agreement with Walmart, causing significant premarket gains. The community is actively discussing potential price targets and whether the stock can sustain its momentum, while also considering potential resistance levels. This development marks AXIL's largest retail placement, expanding access to its hearing protection products.

Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. The firm's antibody therapy, ersodetug, is designed to treat all forms of hyperinsulinism. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada in March 2010 and is headquartered in Redwood City, CA.

Rezolute Inc

Rezolute Inc is trending downwards following the announcement of failed phase 3 trials, leading to a significant drop in stock price and triggering disappointment among investors who had anticipated positive data. The community is discussing the potential reasons for the data miss, possible future actions for the company given its cash reserves, and whether a rebound is possible, while some traders are exploring potential shorting opportunities or bottom-fishing strategies.

iRobot Corp. is a robot company, which engages in designing and building robots. The firm's products include robot vacuums and maps, and pool cleaners. It operates through Domestic and International geographical segments. The company was founded by Rodney Allen Brooks, Colin M. Angle, and Helen Greiner in August 1990 and is headquartered in Bedford, MA.

Irobot Corp

iRobot Corp

IRBT is trending as traders discuss a potential short squeeze, citing very high short interest and recent price movement. Community members are pointing to the difficulty in borrowing shares and high borrowing fees as further indicators of a possible squeeze. Some are expressing caution, noting the company's fundamentals and potential for a bull trap.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending amid discussions about a potential buyout and the company's recent progress in its DM1 clinical study. Community members are debating the stock's valuation, upcoming milestones, and the potential impact of competitor data, while also analyzing recent analyst ratings and institutional ownership.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is trending downwards amidst analyst downgrades, most recently from BofA and JP Morgan, with concerns stemming from slowing growth in branded checkout and a perceived lack of management confidence. The community is debating the impact of buybacks, the CEO's performance, and whether the stock is undervalued or a value trap. Some traders express frustration, while others see an opportunity for long-term gains if PayPal can turn things around.

Beasley Broadcast Group, Inc. is multi-platform media company, which engages in the operation of radio stations in the United States. The firm offers marketing solutions across event platforms. It operates through the following business segments: Audio, Digital, and Other. The company was founded by George G. Beasley in 1961 and is headquartered in Naples, FL.

Beasley Broadcast Group Inc - Ordinary Shares - Class A

BBGI is trending due to a massive intraday price surge, fueled by its low float and significant volume, leading to discussions about potential short squeezes and comparisons to other recent high-flying stocks. The community is actively debating whether the run has ended or if there is potential for further gains, with some cautioning about bag holding and others anticipating after-hours momentum. Overall, traders are focused on the stock's volatile price action and potential for quick profits.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

TTD is trending as it approaches new lows, sparking discussions about its future and potential S&P 500 exclusion. The community is debating factors like competition from Amazon, tax-loss harvesting, and the CEO's performance amid the stock's significant year-to-date decline. Some investors see a buying opportunity, while others express concerns about the company's ability to compete and innovate.

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is trending as traders debate whether its S&P 500 inclusion justifies its high valuation, with some calling it a "scam" and others predicting further gains. Community discussions revolve around potential short squeezes, the influence of interest rate cuts, and concerns about the company's fundamentals versus market hype. Despite the debate, the stock's strong upward momentum has captured significant attention.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Vanda Pharmaceuticals Inc. $VNDA Holdings Cut by Schroder Investment Management Group

Schroder Investment Management Group reduced its stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 53.9% during the 2nd quarter, according to the company in its most recent...

Stonepine Capital Management LLC Has $1.18 Million Position in Vanda Pharmaceuticals Inc. $VNDA

Stonepine Capital Management LLC increased its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) by 611.3% in the second quarter, according to the company in its most...

FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness

FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness PR Newswire WASHINGTON, Dec. 4, 2025 WASHINGTON, Dec. 4, 2025...

Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Rating Lowered by Wall Street Zen

Wall Street Zen cut shares of Vanda Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday...

<ul class="summary-bullets"><li>The postponement was to accommodate the leadership shift at the Center for Drug Evaluation and Research, the company said.&nbsp;</li><li>Vanda continues to expect the agency to decide on its application seeking approval for Tradipitant for the prevention of vomiting induced by motion by December 30.&nbsp;</li><li>The company said it has commenced discussions on the drug’s proposed labeling.</li></ul>Vanda Pharmaceuticals Inc. (VNDA) said on Friday that the U.S. Food and Drug Administration (FDA)’s re-review of the clinical hold on long-term clinical studies of Tradipitant in motion sickness has been extended.The FDA was initially expected to complete the re-review on November 26 and has since then extended it to December 5 to accommodate the leadership shift at the Center for Drug Evaluation and Research, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-provides-regulatory-update-on-tradipitant-for-motion-sickness-302627878.html">said</a>.<h2 class="st-heading-2">Fresh Dates</h2>Vanda expects the agency to decide on its application seeking approval for Tradipitant for the prevention of vomiting induced by motion by December 30, according to previous schedule.The company said it has commenced discussions on the drug’s proposed labeling.Vanda licensed Tradipitant from American drugmaker Eli Lilly and Company. It is being developed for multiple conditions, including gastroparesis, motion sickness, and the prevention of nausea and vomiting induced by GLP-1 receptor agonists.Earlier this month, the company announced that Tradipitan reduced nausea and vomiting induced by GLP-1 drug Wegovy in overweight and obese adults by about 50%. The company is looking forward to a late-stage trial for the condition in the first half of 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of VNDA traded 3% higher on Friday morning. On Stocktwits, retail sentiment around VNDA stock fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.A Stocktwits user highlighted that the company does not expect a delay in its drug application decision.<stembedurl>https://stocktwits.com/Massimo21/message/637642514</stembedurl><a href="https://stocktwits.com/symbol/VNDA">VNDA stock</a> is up by 14% this year and by 6% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/baidu-reportedly-begins-layoffs-in-bid-to-cut-costs-after-disappointing-quarter/cL5aTUpRELQ">Baidu Reportedly Begins Layoffs In Bid To Cut Costs After Disappointing Quarter, AI Roles Largely Safe</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Vanda Pharmaceuticals Says FDA Will Take More Time To Decide On Tradipitant Clinical Hold Re-Review 

The FDA was initially expected to complete the re-review on November 26 and has since then extended it to December 5.

Equity

Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness

Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness PR Newswire WASHINGTON, Nov...

VNDA Stock Jumps on Upbeat Tradipitant Data Cutting GLP-1 Side Effects

Vanda Pharmaceuticals stock rallies after phase II data show tradipitant sharply cuts Wegovy-related nausea and vomiting in overweight and obese adults.

Vanda Pharmaceuticals Surges 21% After Positive Tradipitant Trial In GLP-1 Adjunct Setting

(RTTNews) - Vanda Pharmaceuticals Inc. (VNDA) jumped 21.02% to $5.32, up $0.92, after announcing positive topline results from its phase III study of tradipitant in preventing nausea and vomiting...

Side Effects From Wegovy? This Vanda Pharmaceuticals' Drug Halves Vomiting In Patients

Vanda Pharmaceuticals' tradipitant successfully reduced Wegovy-induced vomiting by 50% in a clinical trial. Phase 3 anticipated in H1 2026.read more...

Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting

Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1...

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

VNDA
Vanda Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest VNDA News

VNDAVanda Pharmaceuticals Inc